{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:00:10Z","timestamp":1790650810139,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100023326","name":"Britannia Pharmaceuticals","doi-asserted-by":"publisher","award":["Britannia Pharmaceuticals"],"award-info":[{"award-number":["Britannia Pharmaceuticals"]}],"id":[{"id":"10.13039\/501100023326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00702-025-03033-8","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T14:41:53Z","timestamp":1759761713000},"page":"779-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of levodopa\u2013entacapone\u2013carbidopa intrajejunal infusion on non-motor symptoms of advanced Parkinson\u2019s disease\u2014interim analysis of the ELEGANCE study"],"prefix":"10.1007","volume":"133","author":[{"given":"Tobias","family":"Warnecke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Odin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Garc\u00eda-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Tulb\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traian Flavius","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos Catalin","family":"Jianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra Bago","family":"Ro\u017eankovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teus","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"3033_CR2","doi-asserted-by":"publisher","unstructured":"Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, investigators Gs (2015) coordinators Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson\u2019s disease patients; 12-month interim outcomes. Parkinsonism & related disorders 21 (3):231\u2013235. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.12.012","DOI":"10.1016\/j.parkreldis.2014.12.012"},{"key":"3033_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.parkreldis.2017.09.018","volume":"45","author":"A Antonini","year":"2017","unstructured":"Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtosek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P, co-investigators Gs (2017) Levodopa-carbidopa intestinal gel in advanced parkinson\u2019s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13\u201320. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.09.018","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"3033_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.24227","volume":"18","author":"I Boura","year":"2025","unstructured":"Boura I, Poplawska-Domaszewicz K, Spanaki C, Chen R, Urso D, van Coller R, Storch A, Chaudhuri KR (2025) Non-Motor fluctuations in parkinson\u2019s disease: underdiagnosed yet important. J Mov Disord 18(1):1\u201316. https:\/\/doi.org\/10.14802\/jmd.24227","journal-title":"J Mov Disord"},{"key":"3033_CR5","doi-asserted-by":"publisher","unstructured":"Chaudhuri KR, Martinez-Martin P (2008) Quantitation of non-motor symptoms in Parkinson\u2019s disease. Eur J Neurology: Official J Eur Federation Neurol Soc 15 Suppl 22\u20137. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02212.x","DOI":"10.1111\/j.1468-1331.2008.02212.x"},{"issue":"13","key":"3033_CR6","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH (2007) The metric properties of a novel non-motor symptoms scale for parkinson\u2019s disease: results from an international pilot study. Mov Disorders: Official J Mov Disorder Soc 22(13):1901\u20131911. https:\/\/doi.org\/10.1002\/mds.21596","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"issue":"5","key":"3033_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3233\/JPD-225105","volume":"13","author":"KR Chaudhuri","year":"2023","unstructured":"Chaudhuri KR, Kovacs N, Pontieri FE, Aldred J, Bourgeois P, Davis TL, Cubo E, Anca-Herschkovitsch M, Iansek R, Siddiqui MS, Simu M, Bergmann L, Ballina M, Kukreja P, Ladhani O, Jia J, Standaert DG (2023) Levodopa carbidopa intestinal gel in advanced parkinson\u2019s disease: DUOGLOBE final 3-Year results. J Parkinson\u2019s Disease 13(5):769\u2013783. https:\/\/doi.org\/10.3233\/JPD-225105","journal-title":"J Parkinson\u2019s Disease"},{"key":"3033_CR7","doi-asserted-by":"publisher","unstructured":"Dafsari HS, Martinez-Martin P, Rizos A, Trost M, Dos Santos Ghilardi MG, Reddy P, Sauerbier A, Petry-Schmelzer JN, Kramberger M, Borgemeester RWK, Barbe MT, Ashkan K, Silverdale M, Evans J, Odin P, Fonoff ET, Fink GR, Henriksen T, Ebersbach G, Pirtosek Z, Visser-Vandewalle V, Antonini A, Timmermann L, Ray Chaudhuri K (2019) Europar, the International P, Movement Disorders Society Non-Motor Parkinson\u2019s Disease Study G EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson\u2019s disease. Movement disorders: official journal of the Movement Disorder Society. https:\/\/doi.org\/10.1002\/mds.27626","DOI":"10.1002\/mds.27626"},{"issue":"5","key":"3033_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1474-4422(20)30036-3","volume":"19","author":"RMA de Bie","year":"2020","unstructured":"de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE (2020) Initiation of Pharmacological therapy in parkinson\u2019s disease: when, why, and how. Lancet Neurol 19(5):452\u2013461. https:\/\/doi.org\/10.1016\/S1474-4422(20)30036-3","journal-title":"Lancet Neurol"},{"issue":"5","key":"3033_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S1474-4422(22)00085-0","volume":"21","author":"VC De Cock","year":"2022","unstructured":"De Cock VC, Dodet P, Leu-Semenescu S, Aerts C, Castelnovo G, Abril B, Drapier S, Olivet H, Corbille AG, Leclair-Visonneau L, Sallansonnet-Froment M, Lebouteux M, Anheim M, Ruppert E, Vitello N, Eusebio A, Lambert I, Marques A, Fantini ML, Devos D, Monaca C, Benard-Serre N, Lacombe S, Vidailhet M, Arnulf I, Doulazmi M, Roze E (2022) Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with parkinson\u2019s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol 21(5):428\u2013437. https:\/\/doi.org\/10.1016\/S1474-4422(22)00085-0","journal-title":"Lancet Neurol"},{"issue":"9","key":"3033_CR10","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1111\/ene.15386","volume":"29","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, Smilowska K, Berg D, Corvol JC, Fabbrini G, Ferreira J, Foltynie T, Mir P, Schrag A, Seppi K, Taba P, Ruzicka E, Selikhova M, Henschke N, Villanueva G, Moro E (2022) European academy of Neurology\/Movement disorder Society - European section guideline on the treatment of parkinson\u2019s disease: I. Invasive therapies. Eur J Neurology: Official J Eur Federation Neurol Soc 29(9):2580\u20132595. https:\/\/doi.org\/10.1111\/ene.15386","journal-title":"Eur J Neurology: Official J Eur Federation Neurol Soc"},{"key":"3033_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.parkreldis.2019.02.043","volume":"64","author":"M Fabbri","year":"2019","unstructured":"Fabbri M, Coelho M, Abreu D, Guedes LC, Rosa MM, Godinho C, Cardoso R, Guimaraes I, Antonini A, Zibetti M, Lopiano L, Ferreira JJ (2019) Dysphagia predicts poor outcome in late-stage parkinson\u2019s disease. Parkinsonism Relat Disord 64:73\u201381. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.02.043","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"3033_CR12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3233\/JPD-160886","volume":"6","author":"G Fernandez-Pajarin","year":"2016","unstructured":"Fernandez-Pajarin G, Sesar A, Ares B, Castro A (2016) Evaluating the efficacy of nocturnal continuous subcutaneous apomorphine infusion in sleep disorders in advanced parkinson\u2019s disease: the APO-NIGHT study. J Parkinson\u2019s Disease 6(4):787\u2013792. https:\/\/doi.org\/10.3233\/JPD-160886","journal-title":"J Parkinson\u2019s Disease"},{"key":"3033_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27372","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C, Movement Disorder Society Evidence-Based Medicine C (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of parkinson\u2019s disease. Mov Disorders: Official J Mov Disorder Soc. https:\/\/doi.org\/10.1002\/mds.27372","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"issue":"1","key":"3033_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/14737175.2023.2176222","volume":"23","author":"WH Jost","year":"2023","unstructured":"Jost WH (2023) A novel treatment option for intrajejunal Levodopa administration. Expert Rev Neurother 23(1):9\u201313. https:\/\/doi.org\/10.1080\/14737175.2023.2176222","journal-title":"Expert Rev Neurother"},{"key":"3033_CR15","unstructured":"LECIGON Summary of Product Characteristics (2022) https:\/\/www.medicines.org.uk\/emc\/product\/14160\/smpc"},{"issue":"19","key":"3033_CR18","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1212\/WNL.0b013e3181c0d416","volume":"73","author":"P Martinez-Martin","year":"2009","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhattacharyya KB, Bloem BR, Carod-Artal FJ, Prakash R, Esselink RA, Falup-Pecurariu C, Gallardo M, Mir P, Naidu Y, Nicoletti A, Sethi K, Tsuboi Y, van Hilten JJ, Visser M, Zappia M, Chaudhuri KR (2009) International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 73(19):1584\u20131591. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c0d416","journal-title":"Neurology"},{"issue":"3","key":"3033_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mds.23462","volume":"26","author":"P Martinez-Martin","year":"2011","unstructured":"Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR (2011) The impact of non-motor symptoms on health-related quality of life of patients with parkinson\u2019s disease. Mov Disorders: Official J Mov Disorder Soc 26(3):399\u2013406. https:\/\/doi.org\/10.1002\/mds.23462","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"issue":"1","key":"3033_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/ene.12165","volume":"22","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG (2015a) Assessing the non-motor symptoms of parkinson\u2019s disease: MDS-UPDRS and NMS scale. Eur J Neurology: Official J Eur Federation Neurol Soc 22(1):37\u201343. https:\/\/doi.org\/10.1111\/ene.12165","journal-title":"Eur J Neurology: Official J Eur Federation Neurol Soc"},{"issue":"4","key":"3033_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.26067","volume":"30","author":"P Martinez-Martin","year":"2015","unstructured":"Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P, Henriksen T, Martin A, Calandrella D, Rizos A, Bryndum N, Glad A, Dafsari HS, Timmermann L, Ebersbach G, Kramberger MG, Samuel M, Wenzel K, Tomantschger V, Storch A, Reichmann H, Pirtosek Z, Trost M, Svenningsson P, Palhagen S, Volkmann J, Chaudhuri KR (2015b) EuroInf: A multicenter comparative observational study of apomorphine and Levodopa infusion in parkinson\u2019s disease. Mov Disorders: Official J Mov Disorder Soc 30(4):510\u2013516. https:\/\/doi.org\/10.1002\/mds.26067","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"issue":"11","key":"3033_CR20","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00702-023-02656-z","volume":"130","author":"HR Moes","year":"2023","unstructured":"Moes HR, Henriksen T, Slawek J, Phokaewvarangkul O, Buskens E, van Laar T (2023) Tools and criteria to select patients with advanced parkinson\u2019s disease for device-aided therapies: a narrative review. J Neural Transm (Vienna) 130(11):1359\u20131377. https:\/\/doi.org\/10.1007\/s00702-023-02656-z","journal-title":"J Neural Transm (Vienna)"},{"issue":"Suppl 1","key":"3033_CR21","doi-asserted-by":"publisher","first-page":"S119","DOI":"10.1016\/j.parkreldis.2015.09.004","volume":"22","author":"RF Pfeiffer","year":"2016","unstructured":"Pfeiffer RF (2016) Non-motor symptoms in parkinson\u2019s disease. Parkinsonism Relat Disord 22(Suppl 1):S119\u2013122. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.09.004","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"3033_CR22","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00702-023-02708-4","volume":"130","author":"Z Pirtosek","year":"2023","unstructured":"Pirtosek Z, Leta V, Jenner P, Verin M (2023) Should continuous dopaminergic stimulation be a standard of care in advanced parkinson\u2019s disease? J Neural Transm (Vienna) 130(11):1395\u20131404. https:\/\/doi.org\/10.1007\/s00702-023-02708-4","journal-title":"J Neural Transm (Vienna)"},{"issue":"6","key":"3033_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/17434440.2025.2499153","volume":"22","author":"K Poplawska-Domaszewicz","year":"2025","unstructured":"Poplawska-Domaszewicz K, Metta V, Odin P, Chaudhuri KR (2025) The device-aided intrajejunal delivery of levodopa-entacapone-carbidopa intestinal gel the treatment of parkinson\u2019s disease: overview of efficacy and safety. Expert Rev Med Devices 22(6):533\u2013544. https:\/\/doi.org\/10.1080\/17434440.2025.2499153","journal-title":"Expert Rev Med Devices"},{"key":"3033_CR24","doi-asserted-by":"crossref","unstructured":"Poplawska-Domszewicz K, Chaudhuri KR (2024) Subcutaneous foslevodopa\/foscarbidopa: A novel 24\u00a0h delivery option for levodopa. In: Odin P, Chaudhuri KR, Falup-Pecurariu C (eds) Device-Aided Therapies in Parkinson\u2019s disease, vol 7. Elsevier, pp 63\u201379","DOI":"10.1016\/bs.irmvd.2024.05.003"},{"issue":"2","key":"3033_CR25","doi-asserted-by":"publisher","first-page":"e57221","DOI":"10.1371\/journal.pone.0057221","volume":"8","author":"K Ray Chaudhuri","year":"2013","unstructured":"Ray Chaudhuri K, Rojo JM, Schapira AH, Brooks DJ, Stocchi F, Odin P, Antonini A, Brown RJ, Martinez-Martin P (2013) A proposal for a comprehensive grading of parkinson\u2019s disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS ONE 8(2):e57221. https:\/\/doi.org\/10.1371\/journal.pone.0057221","journal-title":"PLoS ONE"},{"key":"3033_CR26","doi-asserted-by":"publisher","unstructured":"Santos-Garcia D, de Deus Fonticoba T, Bartolome CC, Painceiras MJF, Castro ES, Canfield H, Miro CM, Jesus S, Aguilar M, Pastor P, Planellas L, Cosgaya M, Caldentey JG, Caballol N, Legarda I, Hernandez-Vara J, Cabo I, Manzanares LL, Aramburu IG, Rivera MAA, Mayordomo VG, Nogueira V, Puente V, Garcia-Soto JD, Borrue C, Vila BS, Sauco MA, Vela L, Escalante S, Cubo E, Padilla FC, Castrillo JCM, Alonso PS, Losada MGA, Ariztegui NL, Gaston I, Kulisevsky J, Estrada MB, Seijo M, Martinez JR, Valero C, Kurtis M, de Fabregues O, Ardura JG, Redondo RA, Ordas C, Diaz LML, McAfee D, Martinez-Martin P, Mir P, Coppadis Study G (2022) Motor Fluctuations Development Is Associated with Non-Motor Symptoms Burden Progression in Parkinson\u2019s Disease Patients: A 2-Year Follow-Up Study. Diagnostics (Basel) 12(5). https:\/\/doi.org\/10.3390\/diagnostics12051147","DOI":"10.3390\/diagnostics12051147"},{"issue":"11","key":"3033_CR27","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00702-024-02773-3","volume":"131","author":"N Schroter","year":"2024","unstructured":"Schroter N, Sajonz BEA, Jost WH, Rijntjes M, Coenen VA, Groppa S (2024) Advanced therapies in parkinson\u2019s disease: an individualized approach to their indication. J Neural Transm (Vienna) 131(11):1285\u20131293. https:\/\/doi.org\/10.1007\/s00702-024-02773-3","journal-title":"J Neural Transm (Vienna)"},{"issue":"2","key":"3033_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/mds.26855","volume":"32","author":"M Senek","year":"2017","unstructured":"Senek M, Nielsen EI, Nyholm D (2017) Levodopa-entacapone-carbidopa intestinal gel in parkinson\u2019s disease: A randomized crossover study. Mov Disorders: Official J Mov Disorder Soc 32(2):283\u2013286. https:\/\/doi.org\/10.1002\/mds.26855","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"issue":"12","key":"3033_CR29","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A, Kimber TE, Klos K, Litvan I, O\u2019Neill D (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21(12):1099\u20131109","journal-title":"Lancet Neurol"},{"issue":"7","key":"3033_CR30","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mdc3.13239","volume":"8","author":"DG Standaert","year":"2021","unstructured":"Standaert DG, Aldred J, Anca-Herschkovitsch M, Bourgeois P, Cubo E, Davis TL, Iansek R, Kovacs N, Pontieri FE, Siddiqui MS, Simu M, Bergmann L, Kukreja P, Robieson WZ, Chaudhuri KR (2021) DUOGLOBE: One-Year outcomes in a Real-World study of Levodopa carbidopa intestinal gel for parkinson\u2019s disease. Mov Disord Clin Pract 8(7):1061\u20131074. https:\/\/doi.org\/10.1002\/mdc3.13239","journal-title":"Mov Disord Clin Pract"},{"issue":"12","key":"3033_CR31","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s00702-015-1437-x","volume":"122","author":"A Storch","year":"2015","unstructured":"Storch A, Schneider CB, Klingelhofer L, Odin P, Fuchs G, Jost WH, Martinez-Martin P, Koch R, Reichmann H, Chaudhuri KR, NoMoFlu PD, Ebersbach G (2015) Quantitative assessment of non-motor fluctuations in parkinson\u2019s disease using the Non-Motor symptoms scale (NMSS). J Neural Transm (Vienna) 122(12):1673\u20131684. https:\/\/doi.org\/10.1007\/s00702-015-1437-x","journal-title":"J Neural Transm (Vienna)"},{"key":"3033_CR32","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/bs.irn.2017.03.001","volume":"132","author":"J Timpka","year":"2017","unstructured":"Timpka J, Nitu B, Datieva V, Odin P, Antonini A (2017) Device-Aided treatment strategies in advanced parkinson\u2019s disease. Int Rev Neurobiol 132:453\u2013474. https:\/\/doi.org\/10.1016\/bs.irn.2017.03.001","journal-title":"Int Rev Neurobiol"},{"issue":"4","key":"3033_CR33","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kohnen R, Hogl B, Metta V, Sixel-Doring F, Frauscher B, Hulsmann J, Martinez-Martin P, Chaudhuri KR (2011) Parkinson\u2019s disease sleep scale\u2013validation of the revised version PDSS-2. Mov Disorders: Official J Mov Disorder Soc 26(4):644\u2013652. https:\/\/doi.org\/10.1002\/mds.23476","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"issue":"s1","key":"3033_CR34","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-181476","volume":"8","author":"DJ van Wamelen","year":"2018","unstructured":"van Wamelen DJ, Grigoriou S, Chaudhuri KR, Odin P (2018) Continuous drug delivery aiming continuous dopaminergic stimulation in parkinson\u2019s disease. J Parkinson\u2019s Disease 8(s1):S65\u2013S72. https:\/\/doi.org\/10.3233\/JPD-181476","journal-title":"J Parkinson\u2019s Disease"},{"issue":"1","key":"3033_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ane.13336","volume":"143","author":"DJ van Wamelen","year":"2021","unstructured":"van Wamelen DJ, Martinez-Martin P, Weintraub D, Schrag A, Antonini A, Falup-Pecurariu C, Odin P, Ray Chaudhuri K, International P, Movement Disorder Society Parkinson\u2019s Disease Non-Motor Study G (2021) The Non-Motor symptoms scale in parkinson\u2019s disease: validation and use. Acta Neurol Scand 143(1):3\u201312. https:\/\/doi.org\/10.1111\/ane.13336","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"3033_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41531-022-00295-x","volume":"8","author":"T Warnecke","year":"2022","unstructured":"Warnecke T, Schafer KH, Claus I, Del Tredici K, Jost WH (2022) Gastrointestinal involvement in parkinson\u2019s disease: pathophysiology, diagnosis, and management. NPJ Parkinsons Dis 8(1):31. https:\/\/doi.org\/10.1038\/s41531-022-00295-x","journal-title":"NPJ Parkinsons Dis"},{"key":"3033_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70046","author":"D Weiss","year":"2025","unstructured":"Weiss D, Jost WH, Szasz JA, Pirtosek Z, Milanov I, Tomantschger V, Kovacs N, Staines H, Amlani B, Smith N, van Laar T (2025) Levodopa-Entacapone-Carbidopa intrajejunal infusion in advanced parkinson\u2019s Disease - Interim analysis of the ELEGANCE study. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70046","journal-title":"Mov Disord Clin Pract"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03033-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:56:45Z","timestamp":1778072205000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03033-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["3033"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03033-8","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TW has received speaker fees\/honoraria from Bial, AbbVie, Merz, Desitin, Pfizer, Britannia Pharmaceuticals Ltd., Zambon, Neuraxpharm, Esteve, and Licher; payment for travel, accommodation, subsistence and conference registration from AbbVie; payment for expert advice from Stadapharm, Bial, Merz, AbbVie, and Phagenesis; funding for research from AbbVie, and Ever Pharma. PO has received honoraria for lectures and expert advice from AbbVie, Bial, Britannia Pharmaceuticals Ltd., Convatec, Ever Pharma, Global Kinetics, Insightech, Merz, Navamedic, Nordic Infucare, Stada, and Zambon. RG-R has received honoraria for lectures and expert advice from AbbVie, Bial, Britannia Pharmaceuticals Ltd., Insightech, Merz, Esteve, Orion, Ipsen, Italfarmaco, Stada, and Zambon. LLM has received honoraria from Abbott, AbbVie, Bial, Biogen, Britannia Pharmaceuticals Ltd., Esteve, Italfarmaco, Lundbeck, Merz and Orion. DT has received honoraria for lectures from AbbVie and Stada. TFD has received honoraria for lectures and expert advice from Stada, AbbVie, BleuPharma, SunWave Pharma and Terapia S.A. DCJ has received lecture fees from AbbVie, and Stada. PBR has received honoraria for lectures and expert advice from AbbVie, Stada, and Medis Adria. TvL has received study support from UMCG, the Dutch Brain Foundation and the Michael J Fox Foundation; lecture fees from AbbVie, Ever Pharma, Britannia Pharmaceuticals Ltd., and Novartis; Advisory Board fees from Britannia Pharmaceuticals Ltd., Centrafarm, AbbVie, Merz Pharma, and Umecrine.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with principles for human experimentation as defined in the Declaration of Helsinki and International Conference on Harmonization Good Clinical Practice guidelines, and approved by all the relevant institutional review boards in each country. Informed consent was obtained from each study participant after they were told of the potential risks and benefits as well as the investigational nature of the study. We confirm that all authors have read the Journal\u2019s guidelines on compliance with ethical standards and affirm that this work is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}